Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones-Reference-Cited by-同舟云学术

Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones

Published:2022-11-01 Issue:11 Volume:38 Page:840-846
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Yager Jenna¹^ORCID,Brooks Kristina M.¹,Brothers Jennifer²,Mulligan Kathleen³,Landovitz Raphael⁴,Reirden Daniel⁵,Glenny Carrie⁵,Malhotra Meena²,Anderson Peter L.¹,Hosek Sybil²

Affiliation:

1. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.

2. Department of Psychiatry, Stroger Hospital of Cook County, Chicago, Illinois, USA.

3. Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, San Francisco, California, USA.

4. Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

5. Department of Adolescent Medicine, Children's Hospital of Colorado, Aurora, Colorado, USA.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2022.0043

Reference15 articles.

1. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial

2. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

3. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

4. Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

5. Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical pharmacology in adolescent transgender medicine;British Journal of Clinical Pharmacology;2024-08-26

2. Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV;British Journal of Clinical Pharmacology;2024-06-12

3. HIV preexposure prophylaxis in adolescents and young adults: an update;Current Opinion in Pediatrics;2024-04-10

4. Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review;Pharmaceutics;2023-10-18

5. Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spots using LC–MS;Bioanalysis;2023-07